50 studies found for:    Open Studies | "Cytomegalovirus Infections"
Show Display Options
Rank Status Study
21 Recruiting Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
Conditions: Sensorineural Hearing Loss;   Cytomegalovirus Infection
Intervention:
22 Recruiting Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant
Conditions: Transplantation Infection;   Cytomegalovirus Infections
Interventions: Drug: Everolimus;   Drug: Very Low Tacrolimus;   Drug: Low Tacrolimus;   Drug: Steroids;   Drug: Thymoglobulin;   Drug: Sodium Mycophenolate
23 Not yet recruiting A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®
Conditions: Adenovirus Infection;   EBV;   Cytomegalovirus Infections;   Cytokine Capture System®;   Allogenic Disease
Intervention: Biological: IFN-γ positive selected T-cells
24 Recruiting Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT
Condition: Cytomegalovirus Infections
Intervention: Biological: CMV Specific T Cell donor lymphocyte infusion
25 Unknown  Cytomegalovirus (CMV) Infection in Amniotic Fluid
Conditions: Pregnancy Complications;   Cytomegalovirus Infections
Intervention:
26 Recruiting Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
Condition: Cytomegalovirus Infections
Interventions: Biological: V160 Low Dose IM;   Biological: V160 Medium Dose IM;   Biological: V160 High Dose IM;   Biological: V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM;   Biological: V160 High Dose plus MAPA 225 µg /dose IM;   Biological: V160 Maximum Dose IM;   Other: Placebo IM;   Biological: V160 Medium Dose ID;   Other: Placebo ID
27 Recruiting Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against Epstein Barr Virus, Adenovirus, And Cytomegalovirus
Conditions: Epstein-Barr Virus Infections;   Adenovirus;   Cytomegalovirus Infections
Intervention: Biological: Cytotoxic T Lymphocytes
28 Recruiting Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus
Conditions: Cytomegalovirus Infections;   Adenovirus Infections
Intervention: Other: Cell therapy
29 Recruiting MK-8228 (Letermovir) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
Condition: Cytomegalovirus Infections
Interventions: Drug: MK-8228;   Drug: Placebo
30 Recruiting ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Conditions: Kidney Transplantation;   Epstein-Barr Virus Infections/Complications;   Cytomegalovirus Infections/Complications
Interventions: Drug: Valacyclovir;   Drug: Valganciclovir
31 Recruiting An Observational Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valcyte (Valganciclovir) Versus Untreated Matched Controls
Condition: Cytomegalovirus Infections, Transplantation
Intervention:
32 Recruiting Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
Conditions: Congenital Cytomegalovirus Infection;   Sensorineural Hearing Loss
Intervention: Drug: Valganciclovir
33 Recruiting Prognostic Value of Neonatal Markers (Clinical, Imaging and Biological) for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus (CMV) in Utero
Condition: Congenital Cytomegalovirus Infection
Intervention: Other: Standardized test report
34 Available Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
Conditions: EBV Infection;   CMV Infection;   Adenoviral Infection
Intervention: Biological: Trivirus-Specific CTLs
35 Recruiting CMV Modulation of the Immune System in ANCA-associated Vasculitis
Conditions: ANCA Associated Vasculitis;   CMV Infection
Intervention: Drug: Valaciclovir
36 Recruiting TT-CMV Observational Birth Cohort Study
Condition: Cytomegalovirus Disease
Intervention:
37 Recruiting Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Kidney Transplant Recipients
Condition: Kidney Transplantation Recipients
Intervention:
38 Recruiting Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®-CMV Test.
Conditions: Renal Transplant Recipient;   Immunized Against the Cytomegalovirus.
Intervention: Biological: CMV Infection
39 Recruiting Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Bone Marrow Transplant Recipients (ACE-BMT)
Condition: Bone Marrow Transplantation
Intervention:
40 Recruiting Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Condition: Cytomegalovirus
Intervention: Genetic: CMV-pp65 CTLs

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-50) Show next page of results    Last Page
Indicates status has not been verified in more than two years